Share This Page
Trimethaphan camsylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for trimethaphan camsylate and what is the scope of patent protection?
Trimethaphan camsylate
is the generic ingredient in one branded drug marketed by Roche and is included in one NDA. Additional information is available in the individual branded drug profile pages.Summary for trimethaphan camsylate
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 17 |
| Clinical Trials: | 3 |
| DailyMed Link: | trimethaphan camsylate at DailyMed |
Recent Clinical Trials for trimethaphan camsylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vanderbilt University | Phase 1 |
Medical Subject Heading (MeSH) Categories for trimethaphan camsylate
US Patents and Regulatory Information for trimethaphan camsylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roche | ARFONAD | trimethaphan camsylate | INJECTABLE;INJECTION | 008983-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Trimethaphan Camsylate Market Dynamics, Financial Trajectory, FDA Status, and Commercial Outlook
Trimethaphan camsylate is a legacy intravenous ganglionic blocker with little current commercial relevance. Its market contracted after newer antihypertensive agents, short-acting vasodilators, anesthetic techniques, and intensive-care protocols displaced it. The product has no meaningful branded-growth trajectory, limited generic incentive, no visible active patent moat, and no publicly reported standalone revenue base. Its remaining value is primarily clinical contingency use rather than volume-driven pharmaceutical growth.
What is trimethaphan camsylate used for?
Trimethaphan camsylate is a short-acting, competitive blocker of autonomic ganglia. It reduces sympathetic and parasympathetic transmission and can produce rapid, controllable decreases in blood pressure.
Historically, the drug was used for:
- Controlled hypotension during surgery
- Hypertensive emergencies
- Acute aortic dissection management
- Reduction of excessive sympathetic activity
- Selected situations requiring rapid, reversible blood-pressure control
The product is administered intravenously and requires close hemodynamic monitoring. Its pharmacology can produce orthostatic hypotension, tachycardia, urinary retention, ileus, blurred vision, and impaired respiratory or gastrointestinal function. These limitations reduced its use as alternatives became easier to administer and more selective.
How does trimethaphan camsylate work?
Trimethaphan blocks transmission at autonomic ganglia. Its effect begins rapidly and generally declines after the infusion stops, which historically made it useful for controlled hypotension. The same nonselective mechanism limits its safety margin and creates management problems involving bowel, bladder, cardiac, and ocular function.
What is the FDA regulatory status of trimethaphan camsylate?
Trimethaphan camsylate was approved in the United States decades ago under the Arfonad brand. The U.S. product is now a legacy or discontinued commercial product rather than a growth-stage FDA medicine. FDA labeling and DailyMed records identify trimethaphan camsylate as an injectable product supplied for dilution and intravenous administration (U.S. Food and Drug Administration [FDA], n.d.; National Library of Medicine [NLM], n.d.).
| Regulatory and commercial item | Status |
|---|---|
| Active ingredient | Trimethaphan camsylate |
| Therapeutic class | Ganglionic blocker; short-acting antihypertensive |
| Primary dosage form | Intravenous injection or infusion |
| Historic brand | Arfonad |
| FDA commercial position | Legacy/discontinued product status |
| Current growth indication | None established |
| Biosimilar pathway | Not applicable |
| Small-molecule generic pathway | Potentially applicable, but commercial interest is limited |
| Public standalone revenue | Not reported in major public-company filings |
The distinction between FDA approval history and current commercial availability is important. A drug can retain historical regulatory records while no longer having a stable, actively marketed supply chain.
When did trimethaphan camsylate lose commercial exclusivity?
Trimethaphan camsylate lost practical exclusivity many years ago. Its composition, mechanism, and original approval history are too old for the original product patents to provide a current commercial barrier. Any early compound, formulation, or use patents would have expired under ordinary U.S. patent terms.
The relevant commercial issue is therefore not patent expiry. It is whether a manufacturer can justify production, regulatory maintenance, sterile manufacturing, quality control, and inventory costs for a low-volume injectable.
What patents protect trimethaphan camsylate?
No material current patent estate is apparent for the active ingredient itself. The commercial product is a long-established small molecule, and no active exclusivity comparable to a modern protected specialty drug is evident from its legacy regulatory position.
Potentially relevant intellectual-property categories include:
- Historical composition-of-matter patents
- Manufacturing or crystallization methods
- Sterile injectable formulations
- Packaging and stability systems
- Hospital-use protocols
These categories are unlikely to create a meaningful barrier unless tied to a newly developed formulation or delivery system. No commercially important reformulated trimethaphan product has emerged in the public market.
How large is the trimethaphan camsylate market?
The current market is niche and difficult to quantify because public manufacturers do not report trimethaphan revenue separately. The product lacks the characteristics that usually support a measurable branded market:
- No broad outpatient use
- No chronic-treatment population
- No major promotional infrastructure
- No visible branded price premium
- No significant patent-protected reformulation
- Limited use in modern hypertension protocols
- Small institutional purchasing base
The addressable market is concentrated in hospitals, operating rooms, critical-care units, and specialized emergency settings. Demand is episodic and procurement-driven rather than prescription-driven.
What determines demand for trimethaphan camsylate?
Demand depends on four factors:
- Availability of substitutes. Sodium nitroprusside, nitroglycerin, nicardipine, clevidipine, labetalol, esmolol, and other agents cover many situations once managed with ganglionic blockade.
- Hospital formulary decisions. Hospitals must decide whether a rarely used injectable justifies inventory and expiry risk.
- Manufacturing economics. Low-volume sterile products have high fixed costs relative to sales.
- Clinical familiarity. Anesthesiology and critical-care teams increasingly use agents with more predictable receptor selectivity and established titration protocols.
How does trimethaphan camsylate compare with competing drugs?
| Drug | Main role | Commercial position | Relative advantage over trimethaphan |
|---|---|---|---|
| Nicardipine | IV blood-pressure control | Widely used hospital generic | More selective arterial vasodilation |
| Clevidipine | Rapid IV blood-pressure control | Branded and generic-market presence varies by jurisdiction | Short titration cycle and predictable effect |
| Labetalol | Hypertensive emergencies | Broad hospital use | Familiarity and dual alpha/beta activity |
| Esmolol | Perioperative tachycardia and blood-pressure control | Established hospital product | Very short beta-blocker half-life |
| Sodium nitroprusside | Controlled vasodilation | Long-established injectable | Direct vasodilator action and titratability |
| Nitroglycerin | Ischemia and preload reduction | Broad hospital availability | Established cardiovascular applications |
| Trimethaphan | Ganglionic blockade | Legacy niche | Rapid, reversible autonomic blockade |
Trimethaphan’s pharmacologic breadth is also its commercial weakness. Nonselective autonomic blockade can affect multiple organ systems, while competing agents allow clinicians to target vascular tone, heart rate, or preload more selectively.
What is the financial trajectory for trimethaphan camsylate?
The financial trajectory is best characterized as decline, fragmentation, and possible discontinuation rather than recovery or expansion.
Historical phase: specialist hospital product
Trimethaphan had value when clinicians needed controllable blood-pressure reduction during surgery and in severe hypertension. Its intravenous delivery and rapid offset supported operating-room use.
Mature phase: substitution and volume erosion
The product lost demand as clinicians adopted:
- Intravenous calcium-channel blockers
- Short-acting beta blockers
- Direct vasodilators
- Improved anesthetic management
- More standardized critical-care protocols
These alternatives reduced the need for a broad autonomic blocker.
Late phase: low-volume supply economics
At low demand, the product becomes vulnerable to:
- Expired inventory
- Minimum batch requirements
- Sterile-fill capacity constraints
- Distribution interruptions
- Low reimbursement relative to manufacturing cost
- Regulatory-maintenance costs
- Hospital reluctance to stock infrequently used drugs
No reliable public revenue series supports a current valuation based on trimethaphan sales. The product is not a material revenue driver in the public filings of major diversified pharmaceutical companies, and there is no visible standalone commercial franchise.
What generic entry risks exist for trimethaphan camsylate?
Generic entry risk is structurally high because the active ingredient is old, the clinical use is narrow, and the product does not appear to have meaningful current exclusivity.
The more important risk is the reverse: insufficient generic competition. A low-volume injectable can experience supply instability even after exclusivity has ended because few manufacturers have an economic reason to enter or remain in the market.
For hospitals, the principal commercial risks are:
- Product discontinuation
- Temporary shortage
- Reliance on a single supplier
- Substitution with less familiar agents
- Higher acquisition prices during constrained supply
- Need for protocol changes if the product disappears
A Paragraph IV challenge would have limited commercial importance unless an active formulation or manufacturing patent were identified. The public record does not indicate a significant current Paragraph IV litigation campaign involving trimethaphan camsylate.
What is the Orange Book status of trimethaphan camsylate?
Trimethaphan’s Orange Book relevance is limited. The product’s commercial history predates the modern patent-listing strategies used for high-value medicines. There is no evident current Orange Book patent position capable of supporting a substantial period of delayed generic entry.
| Orange Book issue | Assessment |
|---|---|
| Listed active ingredient | Historically associated with Arfonad and related injectable products |
| Current listed patents | No material active patent barrier apparent |
| New chemical entity exclusivity | Expired decades ago |
| Pediatric exclusivity | Not commercially relevant |
| Generic certification risk | Low practical significance |
| Litigation exposure | No major current patent dispute apparent |
What manufacturing and intellectual-property barriers remain?
Manufacturing, rather than patent protection, is the principal barrier. Trimethaphan camsylate is an injectable hospital product requiring validated sterile production, quality testing, packaging, storage, and distribution.
Possible barriers include:
- Limited sterile injectable capacity
- Small production runs
- Stability requirements
- Specialized institutional demand
- Low inventory turnover
- Supplier qualification requirements
- Regulatory obligations for a legacy product
These constraints can support pricing in a shortage, but they do not create a durable high-margin franchise. A manufacturer would need either a supply-contract advantage, a hospital shortage opportunity, or a broader portfolio strategy to justify continued production.
Which companies are challenging or commercializing trimethaphan camsylate?
No major current competitive campaign around trimethaphan camsylate is apparent. The commercial landscape is more likely to include legacy suppliers, hospital distributors, and occasional generic or specialty-injectable manufacturers than large branded pharmaceutical companies.
The relevant competitors are the substitute drugs and their manufacturers, not competing trimethaphan brands. Companies selling nicardipine, clevidipine, labetalol, esmolol, sodium nitroprusside, and nitroglycerin compete for the same institutional treatment budgets.
What are the likely launch scenarios?
Three scenarios define the product’s remaining market:
| Scenario | Probability profile | Commercial outcome |
|---|---|---|
| Continued niche supply | Most commercially plausible | Low-volume hospital product with limited revenue |
| Shortage-driven re-entry | Possible if a supplier exits | Temporary price and procurement opportunity |
| Broad market revival | Unlikely | Requires new clinical positioning or delivery technology |
A new formulation, premixed infusion, or improved stability profile could create limited differentiation. It would still face a small patient population, entrenched substitutes, and uncertain reimbursement.
Key Takeaways
- Trimethaphan camsylate is a legacy intravenous ganglionic blocker with limited current use.
- Its commercial decline resulted from therapeutic substitution, not from a recent patent cliff.
- No meaningful current patent moat, biosimilar risk, or active Paragraph IV campaign is apparent.
- Public companies do not report a reliable standalone revenue stream for the drug.
- Manufacturing economics and sterile injectable supply constraints are more important than intellectual property.
- The remaining market is institutional, episodic, and primarily tied to contingency use.
- A broad commercial recovery is unlikely without a clinically differentiated formulation or a supply shortage that temporarily restores demand.
FAQs
Is trimethaphan camsylate still commercially available?
Availability depends on jurisdiction, supplier, and hospital distribution channels. The product is generally treated as a legacy or discontinued commercial medicine rather than a routinely stocked modern antihypertensive.
Is trimethaphan camsylate a generic drug?
It is an old small-molecule injectable with no apparent modern exclusivity barrier. Its commercial status is better described as legacy generic or discontinued-product territory, depending on the market.
Does trimethaphan camsylate have biosimilar competition?
No. Biosimilar regulation applies to biologic products. Trimethaphan camsylate is a conventional small molecule.
Could trimethaphan camsylate become commercially valuable during a drug shortage?
Yes, but only temporarily. A shortage of substitute intravenous antihypertensives or a competing supplier’s exit could increase procurement demand. That would not establish durable long-term market growth.
What drug is most likely to replace trimethaphan camsylate?
The replacement depends on the clinical objective. Nicardipine, clevidipine, labetalol, esmolol, sodium nitroprusside, and nitroglycerin are more likely choices in contemporary hospital protocols because they offer more targeted or familiar hemodynamic control.
References
- National Library of Medicine. (n.d.). DailyMed: Trimethaphan camsylate injection and Arfonad labeling. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and discontinued drug products. U.S. Department of Health and Human Services.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
- U.S. Food and Drug Administration. (n.d.). Drug shortages and discontinued drugs database. U.S. Department of Health and Human Services.
More… ↓
